Cargando…

Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation

Despite pharmacological advances such as lenvatinib approval, therapeutic failure of hepatocellular carcinoma (HCC) remains a big challenge due to the complexity of its underlying molecular mechanisms. Neuropilin-1 (NRP1) is a co-receptor involved in several cellular processes associated to chemores...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández-Palanca, Paula, Payo-Serafín, Tania, San-Miguel, Beatriz, Méndez-Blanco, Carolina, Tuñón, María J., González-Gallego, Javier, Mauriz, José L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104874/ https://www.ncbi.nlm.nih.gov/pubmed/36376373 http://dx.doi.org/10.1038/s41401-022-01021-2

Ejemplares similares

Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications
por: Fernández-Palanca, Paula, et al.
Publicado: (2023)

Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies
por: Fernández-Palanca, Paula, et al.
Publicado: (2022)

Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib
por: Fondevila, Flavia, et al.
Publicado: (2021)

Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis
por: Fondevila, Flavia, et al.
Publicado: (2021)

Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: a systematic review with meta-analysis
por: Méndez-Blanco, Carolina, et al.
Publicado: (2021)

Antitumor Effects of Quercetin in Hepatocarcinoma In Vitro and In Vivo Models: A Systematic Review
por: Fernández-Palanca, Paula, et al.
Publicado: (2019)

Beneficial effects of melatonin on liver fibrosis: A systematic review of current biological evidence
por: San‐Miguel, Beatriz, et al.
Publicado: (2022)

Melatonin as an Antitumor Agent against Liver Cancer: An Updated Systematic Review
por: Fernández-Palanca, Paula, et al.
Publicado: (2021)

Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells
por: Méndez-Blanco, Carolina, et al.
Publicado: (2019)

Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
por: Fondevila, Flavia, et al.
Publicado: (2019)

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
por: Méndez-Blanco, Carolina, et al.
Publicado: (2018)

Effects Of Oral Glutamine on Inflammatory and Autophagy Responses in Cancer Patients Treated With Abdominal Radiotherapy: A Pilot Randomized Trial
por: de Urbina, Juan J. Ortiz, et al.
Publicado: (2017)

Melatonin modulates mitophagy, innate immunity and circadian clocks in a model of viral‐induced fulminant hepatic failure
por: Crespo, Irene, et al.
Publicado: (2020)

Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy
por: Prieto-Domínguez, Néstor, et al.
Publicado: (2017)

Protective Effect of Protocatechuic Acid on TNBS-Induced Colitis in Mice Is Associated with Modulation of the SphK/S1P Signaling Pathway
por: Crespo, Irene, et al.
Publicado: (2017)

Neuropilin-1 in Transplantation Tolerance
por: Campos-Mora, Mauricio, et al.
Publicado: (2013)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Elevated expression of neuropilin-2 associated with unfavorable prognosis in hepatocellular carcinoma
por: Dong, Xiaogang, et al.
Publicado: (2017)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022)

Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma
por: Merle, Philippe
Publicado: (2023)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Distinct Roles for Neuropilin1 and Neuropilin2 during Mouse Corneal Innervation
por: McKenna, Chelsey C., et al.
Publicado: (2012)

Endothelial VEGFR Coreceptors Neuropilin-1 and Neuropilin-2 Are Essential for Tumor Angiogenesis
por: Benwell, Christopher J., et al.
Publicado: (2022)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
por: Hou, Fang-jie, et al.
Publicado: (2019)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
por: Shintani, Hiroshi, et al.
Publicado: (2021)

Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma
por: Rehman, Obaid, et al.
Publicado: (2021)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Lenvatinib-Induced Destructive Thyroiditis in a Patient With Hepatocellular Carcinoma
por: Pandya, Anjani, et al.
Publicado: (2021)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
por: He, Xiaoping, et al.
Publicado: (2022)

Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma
por: Imakura, Takeshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7ikf3btamvrpd4i4c1b2fhbnbm